Failure of alkylating chemotherapy in the treatment of recurrent GBM: the impact of Bevacizumab and Irinotecan as third line therapy

Juliane Schroeteler, Marion Rapp, Marta Wallocha, Phillip Grosser, Hans-Jakob Steiger & Michael Sabel
Objective: Though treatment of primarily diagnosed Glioblastoma multiforme (GBM) has been much improved by the introduction of standardized alkylating chemotherapy, new adjuvant treatment concepts for recurrent GBM after failure of alkylating therapy are needed. Due to their mechanism of action much[for full text, please go to the a.m. URL]